In a move that promises to expand the types of malaria vaccine candidates in clinical development, the PATH Malaria Vaccine Initiative today announced a new partnership with Sanaria Inc., a Maryland company, to accelerate development of a unique malaria vaccine candidate.
Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells, according to a clinical trial led by a University of North Carolina at Chapel Hill School of Medicine researcher.
Although some Americans gain five to seven pounds with a diet of big meals and sweets between Thanksgiving and New Year’s Day, most people only gain a pound or two during the holidays, according to a UT Southwestern Medical Center registered dietitian.
A natural substance made from soy appears to have amazing restorative powers when given to animals with a multiple sclerosis (MS)-like disease.
VIB and AlgoNomics have joined forces to develop a technology that verifies whether certain proteins induce an immune response in humans. The collaboration between VIB and AlgoNomics has yielded a biological test that supplements the current computer simulations. The additional data enable a more precise determination of the immune response.
Thalidomide is a widely prescribed treatment for multiple myeloma. However, an estimated 15 to 30 percent of patients suffer venous thromboembolisms (VTEs), blood clots, as a major complication. The Bank On A Cure DNA-bank researchers have identified four gene clusters associated with the VTEs. Identifying the associated single nucleotide polymorphisms (SNPs) for use as markers, may lead to the development of screenings and tailored interventions to prevent these side effects, as a major step toward personalized medicine.
Most patients undergoing bone-marrow transplant must receive powerful chemotherapy drugs to suppress their immune system and prevent their bodies from rejecting the donated cells. New research shows that this chemotherapy increases the risk for graft-versus-host disease — but also suggests that this risk can be reduced by replacing a natural antibiotic that’s depleted when patients undergo chemotherapy. A multicenter study led by Children’s Hospital Boston and the Dana-Farber Cancer Institute is about to test this idea.
Mayo Clinic Cancer Center, working in collaboration with Ohio State University Comprehensive Cancer Center, presented evidence Sunday that a novel regimen of three chemotherapy drugs, pentostatin, cyclophosphamide and rituximab, resulted in significant clinical response in patients with previously untreated chronic lymphocytic leukemia (CLL).
Back-to-back papers published online this week in Nature Genetics reveal important new details about the genetic variability of the malaria parasite and provide new clues for how it causes disease.
Cancer immunoresistance may be partially due to loss of a well-known tumor suppressor gene, according to new research led by Andrew T. Parsa, MD, PhD, assistant professor of neurological surgery at the University of California, San Francisco.